ClinicalTrials.gg
CompletedNCT00562614Updated Apr 30, 2026

Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension

A Phase 2 interventional study of SLx-2101 in Hypertension, sponsored by Retension Pharmaceuticals. Inc.. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by Retension Pharmaceuticals. Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2007, 18 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 282 studies in Hypertension with a site in Germany — 30 open to participants now, 46 under way, 11 of them phase 3. Hypertension · Germany.

Enrollment
228th of 250
38 · median 200
Started
2007
with 18 others
Phase 2
24 of 282
none open now
Registered
90th of 282
by date

Among the 282 studies in Hypertension with a site in Germany, this one is the 228th largest by enrollment of the 250 interventional ones that give a count, is one of 19 that started in 2007, is one of 24 in phase 2, and was the 90th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

30 of the 282 studies in Hypertension with a site in Germany are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 282 studies in Hypertension with a site in Germany, or all of them as a file.
02

Study summary

The purpose is to determine the effect of SLx-2101 dosed at 5mg or 10mg for 14 days on systolic, diastolic pressures and heart rate in patients with hypertension.

Read the detailed description
  1. Placebo-corrected supine peripheral systolic, diastolic blood pressures and heart rate
  2. 24 hour ambulatory blood pressure and heart rate
  3. Safety and tolerability
03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects between 18 and 70 years old, inclusive
  • Moderate to severe hypertension
  • Body weight within a of 18-32kg/m2

Exclusion criteria

Exclusion Criteria:

  • The subject is receiving more than three antihypertensive agents
  • A history of drug abuse
  • Exposure to a new chemical entity within 3 months prior to the first day of dosing
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    1

    SLx-2101

    Drug: SLx-2101

  • Placebo comparator
    2

    Comparative Placebo Dose

    Drug: SLx-2101

Interventions

06

What researchers measure

Primary outcomes

  1. Peripheral systolic, diastolic blood pressures and heart rates

    Time frame: 14 days

Secondary outcomes

  1. Adverse events

    Time frame: 14 days

07

Study locations

1 site
  • Parexel, Institute for Clinical Pharmacology
    Berlin, D-14050, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2007
First posted
Nov 22, 2007
Start
Jun 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00562614
Lead sponsor
Retension Pharmaceuticals. Inc.
Responsible party
Sponsor
First posted
Nov 22, 2007
Start date
Jun 2007
Primary completion
Dec 2007
Completion
Dec 2007
Last update
Apr 30, 2026

Study contacts

Georg Golor, MD
principal investigator · PAREXEL, Institute for Clinical Pharmacology

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SLX-2101

Start the discussion